Witkin JM - Search Results

1

Behavioral effects and anticonvulsant efficacies of low-affinity, uncompetitive NMDA antagonists in mice.

Geter-Douglass B, Witkin JM. Geter-Douglass B, et al. Among authors: witkin jm. Psychopharmacology (Berl). 1999 Oct;146(3):280-9. doi: 10.1007/s002130051118. Psychopharmacology (Berl). 1999. PMID: 10541728

2

Attenuation of the stimulant and convulsant effects of cocaine by 17-substituted-3-hydroxy and 3-alkoxy derivatives of dextromethorphan.

Zapata A, Gasior M, Geter-Douglass B, Tortella FC, Newman AH, Witkin JM. Zapata A, et al. Among authors: witkin jm. Pharmacol Biochem Behav. 2003 Jan;74(2):313-23. doi: 10.1016/s0091-3057(02)01000-6. Pharmacol Biochem Behav. 2003. PMID: 12479950

3

Discriminative stimulus effects of R-(+)-3-amino-1-hydroxypyrrolid-2-one, [(+)-HA-966], a partial agonist of the strychnine-insensitive modulatory site of the N-methyl-D-aspartate receptor.

Witkin JM, Brave S, French D, Geter-Douglass B. Witkin JM, et al. J Pharmacol Exp Ther. 1995 Dec;275(3):1267-73. J Pharmacol Exp Ther. 1995. PMID: 8531091

4

Dizocilpine-like discriminative stimulus effects of competitive NMDA receptor antagonists in mice.

Geter-Douglass B, Witkin JM. Geter-Douglass B, et al. Among authors: witkin jm. Psychopharmacology (Berl). 1997 Sep;133(1):43-50. doi: 10.1007/s002130050369. Psychopharmacology (Berl). 1997. PMID: 9335079

5

NMDA antagonist properties of the putative antiaddictive drug, ibogaine.

Popik P, Layer RT, Fossom LH, Benveniste M, Geter-Douglass B, Witkin JM, Skolnick P. Popik P, et al. Among authors: witkin jm. J Pharmacol Exp Ther. 1995 Nov;275(2):753-60. J Pharmacol Exp Ther. 1995. PMID: 7473163

6

(+/-)-(N-alkylamino)benzazepine analogs: novel dopamine D1 receptor antagonists.

Shah JH, Izenwasser S, Geter-Douglass B, Witkin JM, Newman AH. Shah JH, et al. Among authors: witkin jm. J Med Chem. 1995 Oct 13;38(21):4284-93. doi: 10.1021/jm00021a018. J Med Chem. 1995. PMID: 7473556

7

Assessment of cocaine-like discriminative stimulus effects of dopamine D3 receptor ligands.

Acri JB, Carter SR, Alling K, Geter-Douglass B, Dijkstra D, Wikström H, Katz JL, Witkin JM. Acri JB, et al. Among authors: witkin jm. Eur J Pharmacol. 1995 Aug 4;281(2):R7-9. doi: 10.1016/0014-2999(95)00411-d. Eur J Pharmacol. 1995. PMID: 7589197

8

(+/-)-3-[4'-(N,N-dimethylamino)cinnamyl]benzazepine analogs: novel dopamine D1 receptor antagonists.

Shah JH, Kline RH, Geter-Douglass B, Izenwasser S, Witkin JM, Newman AH. Shah JH, et al. Among authors: witkin jm. J Med Chem. 1996 Aug 16;39(17):3423-8. doi: 10.1021/jm960143p. J Med Chem. 1996. PMID: 8765528

9

Characterization of unconditioned behavioral effects of dopamine D3/D2 receptor agonists.

Geter-Douglass B, Katz JL, Alling K, Acri JB, Witkin JM. Geter-Douglass B, et al. Among authors: witkin jm. J Pharmacol Exp Ther. 1997 Oct;283(1):7-15. J Pharmacol Exp Ther. 1997. PMID: 9336302

10

Sensitive and rapid behavioral differentiation of N-methyl-D-aspartate receptor antagonists.

Ginski MJ, Witkin JM. Ginski MJ, et al. Among authors: witkin jm. Psychopharmacology (Berl). 1994 May;114(4):573-82. doi: 10.1007/BF02244987. Psychopharmacology (Berl). 1994. PMID: 7855218

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

259 results

Search Page

Filters